In this interview, Spencer King and Marc Bonaca discuss insights from the DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58) trial, specifically dapagliflozin and outcomes in patients with peripheral artery disease.

Subscribe on iTunes | Subscribe on Google Play | Subscribe to ACCEL

Clinical Topics: Diabetes and Cardiometabolic Disease, Prevention, Vascular Medicine, Atherosclerotic Disease (CAD/PAD)

Keywords: ACCELLite, Hemoglobin A, Glycated Hemoglobin A, Diabetes Mellitus, Type 2, Hyperglycemia, Metabolic Syndrome, Primary Prevention, Peripheral Arterial Disease, Ischemia, Amputation

< Back to Listings